PDCD1 and hepatocellular carcinoma: The use of specific antibodies that block activation of these regulatory molecules associated with immune exhaustion (i.e., CTLA-4, PD-1 and PD1-L1), and known ICIs has rapidly extended the therapeutic armamentarium against HCC and other malignancies.